Viking Therapeutics is trading $37.10 (+23.21%) after September 22, 2026, results showed VK2735 patients maintained up to 97% of prior weight loss with every-other-week dosing and up to 90% with monthly dosing.
- Reuters reported shares were up 40% before the bell
- The company cited approximately 22% placebo-adjusted weight loss
- Gastrointestinal safety was comparable to placebo, with favorable tolerability reported